MiR-100 suppresses IGF2 and inhibits breast tumorigenesis by interfering with proliferation and survival signaling

Oncogene

Volumn 32, Issue 27, 2013, Pages 3306-3310

  Gebeshuber, C A ^a,b   Martinez, J ^a  

^a ERICH SCHMID INSTITUTE OF MATERIALS SCIENCE   (Austria)

^b MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

Breast cancer; IGF2; miR 100

Indexed keywords

MAMMALIAN TARGET OF RAPAMYCIN; MICRORNA 100; SOMATOMEDIN B;

APOPTOSIS; ARTICLE; BREAST CARCINOGENESIS; CANCER GROWTH; CANCER INHIBITION; CANCER SURVIVAL; CELL PROLIFERATION; CLINICAL ARTICLE; DOWN REGULATION; FLUORESCENCE ACTIVATED CELL SORTING; HUMAN; HUMAN TISSUE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; WILD TYPE;

ANIMALS; BLOTTING, NORTHERN; BLOTTING, WESTERN; BREAST NEOPLASMS; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; CELL TRANSFORMATION, NEOPLASTIC; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; INSULIN-LIKE GROWTH FACTOR II; MICE; MICRORNAS; MUTAGENESIS, SITE-DIRECTED; POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; TOR SERINE-THREONINE KINASES;

EID: 84880305345     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2012.372     Document Type: Article

References (26)

1. Bartel DP. MicroRNAs: target recognition and regulatory functions. Cell 2009; 136: 215-233.
2. Bazzini AA, Lee MT, Giraldez AJ. Ribosome profiling shows that miR-430 reduces translation before causing mRNA decay in zebrafish. Science 336: 233-237.
3. Calin GA, Croce CM. MicroRNA signatures in human cancers. Nat Rev Cancer 2006; 6: 857-866.
4. Fan C, Oh DS, Wessels L, Weigelt B, Nuyten DS, Nobel AB et al. Concordance among gene-expression-based predictors for breast cancer. N Engl J Med 2006; 355: 560-569.
5. McCann AH, Miller N, O'Meara A, Pedersen I, Keogh K, Gorey T et al. Biallelic expression of the IGF2 gene in human breast disease. Hum Mol Genet 1996; 5: 1123-1127.
6. Pravtcheva DD, Wise TL. Metastasizing mammary carcinomas in H19 enhancers- Igf2 transgenic mice. J Exp Zool 1998; 281: 43-57.
7. Cui H, Horon IL, Ohlsson R, Hamilton SR, Feinberg AP. Loss of imprinting in normal tissue of colorectal cancer patients with microsatellite instability. Nat Med 1998; 4: 1276-1280.
8. Burns JL, Hassan AB. Cell survival and proliferation are modified by insulin-like growth factor 2 between days 9 and 10 of mouse gestation. Development 2001; 128: 3819-3830.
9. Pacher M, Seewald MJ, Mikula M, Oehler S, Mogg M, Vinatzer U et al. Impact of constitutive IGF1/IGF2 stimulation on the transcriptional program of human breast cancer cells. Carcinogenesis 2007; 28: 49-59.
10. Giani C, Cullen KJ, Campani D, Rasmussen A. IGF-II mRNA and protein are expressed in the stroma of invasive breast cancers: an in situ hybridization and immunohistochemistry study. Breast Cancer Res Treat 1996; 41: 43-50.
11. Jones RA, Campbell CI, Gunther EJ, Chodosh LA, Petrik JJ, Khokha R et al. Transgenic overexpression of IGF-IR disrupts mammary ductal morphogenesis and induces tumor formation. Oncogene 2007; 26: 1636-1644.
12. Aslakson CJ, Miller FR. Selective events in the metastatic process defined by analysis of the sequential dissemination of subpopulations of a mouse mammary tumor. Cancer Res 1992; 52: 1399-1405.
13. Kauppinen S, Vester B, Wengel J. Locked nucleic acid: high-affinity targeting of complementary RNA for RNomics. Handb Exp Pharmacol 2006 405-422.
14. Nielsen FC, Ostergaard L, Nielsen J, Christiansen J. Growth-dependent translation of IGF-II mRNA by a rapamycin-sensitive pathway. Nature 1995; 377: 358-362.
15. Garzon R, Marcucci G, Croce CM. Targeting microRNAs in cancer: rationale, strategies and challenges. Nat Rev Drug Discov 2010; 9: 775-789.
16. Dupont J, Khan J, Qu BH, Metzler P, Helman L, LeRoith D. Insulin and IGF-1 induce different patterns of gene expression in mouse fibroblast NIH-3T3 cells: identification by cDNA microarray analysis. Endocrinology 2001; 142: 4969-4975.
17. Tovar V, Alsinet C, Villanueva A, Hoshida Y, Chiang DY, Solé M et al. IGF activation in a molecular subclass of hepatocellular carcinoma and pre-clinical efficacy of IGF-1R blockage 2010J Hepatol 52: 550-559.
18. Nagaraja AK, Creighton CJ, Yu Z, Zhu H, Gunaratne PH, Reid JG et al. A link between mir-100 and FRAP1/mTOR in clear cell ovarian cancer. Mol Endocrinol 2010; 24: 447-463.
19. Shi W, Alajez NM, Bastianutto C, Hui AB, Mocanu JD, Ito E et al. Significance of Plk1 regulation by miR-100 in human nasopharyngeal cancer. Int J Cancer 2010; 126: 2036-2048.
20. Doghman M, El Wakil A, Cardinaud B, Thomas E, Wang J, Zhao W et al. Regulation of insulin-like growth factor-mammalian target of rapamycin signaling by microRNA in childhood adrenocortical tumors. Cancer Res 2010; 70: 4666-4675.
21. Hausser J, Berninger P, Rodak C, Jantscher Y, Wirth S, Zavolan M. MirZ: an integrated microRNA expression atlas and target prediction resource. Nucleic Acids Res 2009; 37: W266-W272.
22. Romero-Cordoba S, Rodriguez-Cuevas S, Rebollar-Vega R, Quintanar-Jurado V, Maffuz-Aziz A, Jimenez-Sanchez G et al. Identification and pathway analysis of microRNAs with no previous involvement in breast cancer. PLoS One 2012; 7: e31904.
23. Pollak M. Insulin, insulin-like growth factors and neoplasia. Best Pract Res Clin Endocrinol Metab 2008; 22: 625-638.
24. Willison K. Opposite imprinting of the mouse Igf2 and Igf2r genes. Trends Genet 1991; 7: 107-109.
25. Sasaki H, Jones PA, Chaillet JR, Ferguson-Smith AC, Barton SC, Reik W et al. Parental imprinting: potentially active chromatin of the repressed maternal allele of the mouse insulin-like growth factor II (Igf2) gene. Genes Dev 1992; 6: 1843-1856.
26. Janda E, Lehmann K, Killisch I, Jechlinger M, Herzig M, Downward J et al. Ras and TGF[beta] cooperatively regulate epithelial cell plasticity and metastasis: dissection of Ras signaling pathways. J Cell Biol 2002; 156: 299-313.